Solstice Advanced Materials, Inc. (NASDAQ: SOLS) delivered a sharp move higher in the latest trading session, with shares climbing 12.76% to close at $63.53 on August 28, 2026. The stock added $7.19 during the session, while after-hours trading showed a further gain of $0.37, or 0.58%, to $63.90.

Trading Volume Jumps Above Average

The rally came alongside unusually strong trading activity. Solstice recorded volume of approximately 16.47 million shares, significantly above its reported average volume of about 3.23 million shares. The surge pushed the company’s intraday market capitalization to approximately $10.09 billion and placed the stock firmly in focus among investors tracking specialty chemicals and advanced materials companies.

Five-Day Momentum Strengthens

The session also marked a substantial breakout from the stock’s recent trading range. SOLS opened at $64.99 and traded between $63.13 and $67.50 before settling at $63.53. Over the preceding five trading days, the stock gained approximately 13.12%, reflecting a sharp acceleration in momentum toward the end of the period. Despite the recent advance, shares remain below their 52-week high of $90.80, while the 52-week low stands at $40.43.

Specialty Chemicals and Advanced Materials Operations

Solstice Advanced Materials operates across two primary business segments: Refrigerants & Applied Solutions (RAS) and Electronic & Specialty Materials (ESM). The RAS segment manufactures and sells low-global-warming-potential refrigerants, blowing agents, solvents and aerosol materials, while also providing aerosol propellants, cleaning solvents, pharmaceutical packaging materials and alternative energy services. Its products operate under brands including Solstice, Genetron and Aclar.

ESM Segment Targets High-Value Markets

The ESM segment focuses on electronic materials, fibers and laboratory life science chemicals serving semiconductor, defense, pharmaceutical and construction markets. Its portfolio includes sputtering targets, lightweight high-strength fibers and high-purity life science solutions under brands such as Spectra, Fluka and Hydranal.

Valuation and Analyst Target

The company’s valuation has also moved higher alongside the stock. SOLS currently carries a trailing price-to-earnings ratio of approximately 42.64, with trailing earnings per share of $1.49. The displayed one-year target estimate is $80.43, suggesting additional upside from the latest closing level if that target is achieved.

Earnings Date Becomes the Next Catalyst

Investor attention is now likely to shift toward Solstice’s upcoming corporate milestones. The company is scheduled to report earnings on October 29, 2026, while a dividend-related date is listed for September 10. The combination of elevated trading volume, strong short-term price momentum and exposure to specialty chemicals and advanced materials could keep SOLS on investors’ watchlists as the market assesses whether the latest rally represents a temporary surge or the beginning of a broader re-rating.